

Discriminant Capacity of Clinical Efficacy and Nonsteroidal Antiinflammatory Drug-sparing Endpoints, Alone or in Combination, in Axial Spondyloarthritis

Maxime Dougados, Emily Wood, Laure Gossec, Arnaud Dubanchet, Isabelle Logeart, and Désirée van der Heijde

ABSTRACT. Objective. Using data from a randomized, double-blind, placebo-controlled study, we assessed the capacity of clinical and nonsteroidal antiinflammatory drug (NSAID)-sparing endpoints, alone and in combination, to discriminate between treatment effects in axial spondyloarthritis (axSpA).

Methods. Patients with active NSAID-resistant axSpA received etanercept (ETN) 50 mg/week or placebo for 8 weeks and tapered/discontinued NSAID. In posthoc logistic regression analyses, OR were calculated that indicated the capacity of the following endpoints to discriminate between the effects of ETN and placebo at Week 8: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50; BASDAI ≤ 3 ; Assessment of Spondyloarthritis international Society (ASAS) 20; ASAS40; Ankylosing Spondylitis Disease Activity Score (ASDAS) with C-reactive protein (CRP) < 1.3 and ASDAS-CRP < 2.1 ; $\geq 50\%$ decrease from baseline in ASAS-NSAID score, score < 10 , and score = 0; and each clinical and/or each NSAID measure.

Results. In 90 randomized patients (ETN, $n = 42$; placebo, $n = 48$), disease activity was similar between groups at baseline: mean (\pm SD) BASDAI (ETN vs placebo) 6.0 ± 1.6 versus 5.9 ± 1.5 . NSAID intake was high: ASAS-NSAID score 98.2 ± 39.0 versus 93.0 ± 23.4 . OR ranged from 1.6 (95% CI 0.5–5.4) for ASDAS-CRP < 1.3 to 5.8 (95% CI 1.2–29.1) for BASDAI50 and NSAID score of 0; most measures (34/45) reached statistical significance ($\alpha = 0.05$) favoring ETN. Most combined outcome variables using OR were more discriminant than single outcome measures.

Conclusion. These findings suggest that changes in NSAID intake during treatment do not prevent demonstration of clinically relevant effects of biologic treatment, and combined (i.e., clinical with NSAID-sparing) endpoints were frequently more discriminant than single (i.e., clinical) endpoints. ClinicalTrials.gov (NCT01298531). (J Rheumatol First Release November 15 2015; doi:10.3899/jrheum.150378)

Key Indexing Terms:

AXIAL SPONDYLOARTHRITIS	NONSTEROIDAL ANTIINFLAMMATORY DRUG		
ETANERCEPT	ASAS	ASDAS	BASDAI

Nonsteroidal antiinflammatory drugs (NSAID) are recommended as first-line pharmacotherapy for axial spondyloarthritis (axSpA) based on evidence that they provide rapid symptomatic relief^{1,2}, reduce acute-phase reactant levels³,

and may slow radiologic progression^{4,5,6}. However, systematic continuous daily intake of NSAID is often required to treat chronic diseases, but may be associated with adverse effects on the gastrointestinal tract^{7,8}, kidneys⁹, and

From the Paris Descartes University; Department of Rheumatology-Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); Institut national de la santé et de la recherche médicale (INSERM; U1153); Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique; Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; Pfizer, Paris, France; Statistical Consultancy, Quanticate Ltd., Hitchin, UK; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.

Sponsored by Pfizer. Dr. Dougados has received consulting fees from Pfizer and his department has received research grants from Pfizer for this study. Ms. Wood was contracted and paid by Pfizer to provide statistical input to the study and manuscript. Dr. Gossec has received consulting fees from Pfizer. Dr. van der Heijde has received consulting fees and/or

research grants from Pfizer. Dr. Dubanchet and Dr. Logeart are employees of Pfizer. Pfizer paid for editorial/medical writing support.

M. Dougados, MD, Paris Descartes University, and Department of Rheumatology-Hôpital Cochin, AP-HP, and INSERM (U1153); Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité; E. Wood, MSc, Statistical Consultancy, Quanticate Ltd.; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Department of Rheumatology, Pitié Salpêtrière Hospital, AP-HP; A. Dubanchet, MD, Pfizer; I. Logeart, MD, Pfizer; D. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center.

Address correspondence to Dr. M. Dougados, Rheumatology B Department, Cochin Hospital, 27 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail: maxime.dougados@cch.aphp.fr

Accepted for publication August 14, 2015.

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2015. All rights reserved.

cardiovascular system^{10,11}. For diseases primarily treated with drugs that are clinically effective but pose a potentially serious safety risk, newer therapies are often introduced to provide equivalent or greater symptomatic improvement while “sparing” use of the potentially toxic conventional therapy. In rheumatic diseases, examples include NSAID-sparing symptomatic slow-acting drugs (e.g., chondroitin sulphate and glucosamine sulphate) in osteoarthritis^{12,13,14,15}, corticosteroid-sparing methotrexate in polymyalgia rheumatica¹⁶, and corticosteroid-sparing biologics in rheumatoid arthritis^{17,18,19,20}.

Treatment with antitumor necrosis factor (anti-TNF) biological agents is recommended in patients with definite axSpA who have high disease activity despite the use of at least 2 NSAID in the prior 4-week period²¹. Although these agents have an acceptable safety record, they are associated with a small but significant risk of serious infections²², particularly at high doses²³. In clinical practice, beyond their clinical efficacy in NSAID-resistant patients, anti-TNF agents may reduce NSAID intake in patients with SpA and therefore decrease the risk of toxicity with longterm NSAID use. However, relatively few clinical trials have assessed the NSAID-sparing effects of such therapies²⁴. In most clinical trials of anti-TNF therapy in axSpA, changes in disease activity measures [e.g., the Assessment of SpondyloArthritis international Society (ASAS) responder criteria] have been selected as primary endpoints, and the use of concomitant NSAID therapy has been either prohibited or required to remain stable during the blinded controlled phase of the study. Such a decision reflects the past and present fear that outcome measures used to assess disease activity would have less discriminant capacity if NSAID intake were substantially reduced in the active treatment arm versus the placebo arm. Moreover, the decision also likely reflects at least in part a lack of consensus on the appropriate methodology to use for the collection and reporting of concomitant therapy intake. Several different techniques have been proposed for the quantification and recording of NSAID intake, including the ASAS scoring system²⁵.

In trials designed to evaluate treatments such as anti-TNF agents with possible NSAID-sparing effects, many questions remain about the discriminant capacity of outcome measures. Specifically, research has not yet shown whether clinical response criteria alone, NSAID response criteria alone, or a combination of such criteria might be more discriminant and therefore might result in a reduction of the number of patients required for inclusion in trials.

In an anti-TNF trial (the SPARSE study), the effect of treatment with the anti-TNF agent etanercept (ETN) on NSAID intake was examined using the latter ASAS-NSAID score²⁵ in patients with axSpA who had been taking NSAID at baseline and were strongly advised to decrease and discontinue their NSAID use thereafter during an initial 8-week, double-blind, placebo-controlled treatment period. Primary

and secondary outcomes of this study have been recently published elsewhere²⁶. Using the SPARSE database, we performed posthoc, exploratory analyses to evaluate the capacity of conventional clinical outcome measures and NSAID-sparing outcome measures, assessed individually and in combination, to discriminate between the treatment effects of ETN and placebo.

MATERIALS AND METHODS

The following sections briefly summarize the methodology of the SPARSE study, which is described in detail in a previous publication²⁶.

Study design. At screening, investigators instructed patients to discontinue their NSAID and restart the NSAID only in case of symptom flare, with treatment adjusted as needed to achieve optimal symptomatic control. Patients who experienced symptom flare after NSAID discontinuation and restarted NSAID treatment, and whose disease remained active, were randomized (1:1) to receive ETN 50 mg or placebo subcutaneously once weekly for 8 weeks, as well as their background NSAID as required. Investigators requested that patients taper and discontinue their NSAID intake during the randomized treatment period if clinically acceptable.

The SPARSE study was conducted in accordance with the International Conference on Harmonisation guidelines for good clinical practice and the Declaration of Helsinki. Study activities were not initiated until the Institutional Review Board approval and the patient-informed consent were obtained.

Patients. Eligible patients had axSpA according to the treating rheumatologist, with active axial involvement defined by a mini-Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4 on a scale of 0 to 10, i.e., $Q1 + Q2 + [(Q5 + Q6) \div 2] \div 3 \geq 4$ ²⁷. An inadequate response was also required to at least 2 NSAID taken at maximum tolerated doses (based on medical history) for a total combined duration of at least 1 month. Patients were ineligible if they received prior treatment with a biologic agent or recent treatment with a corticosteroid or had uncontrolled inflammatory bowel disease or uveitis.

Clinical and NSAID-sparing outcome measures. The conventional clinical endpoints selected *a priori* for analysis, individually and in combination with the ASAS-NSAID score endpoints, included the BASDAI50 response and BASDAI ≤ 3 ²⁸; ASAS20 and ASAS40 responses²⁹; and the Ankylosing Spondylitis Disease Activity Score (ASDAS) based on C-reactive protein (CRP) < 1.3 (inactive disease) and ASDAS-CRP ≥ 1.3 to < 2.1 (moderate disease activity state)³⁰ at 8 weeks. The ASAS-NSAID score is based on the NSAID type, mean daily dose, and number of days with intake. The score was derived from data recorded on patient diary cards for the 7 days prior to the respective visit. Each daily dose of NSAID was converted to a percentage dose equivalent to 150 mg diclofenac. The daily doses were then totaled and the sum divided by the number of days in the period of interest. The minimum value was 0 (no NSAID intake) and a higher ASAS-NSAID value indicated greater NSAID consumption²⁵. The binary ASAS-NSAID score endpoints chosen *a priori* as single outcomes and combined outcomes with clinical endpoints were ASAS-NSAID score of 0, ASAS-NSAID score < 10 , and decrease in ASAS-NSAID score of $\geq 50\%$ from baseline. Dichotomous (rather than continuous) outcomes were used in these analyses because they allowed for the combination of clinical and NSAID-sparing outcome measures and are more easily understood by clinicians.

Statistical analysis. All analyses were performed on the intent-to-treat (ITT) population, which included all randomized patients who received at least 1 dose of study medication. Baseline demographic and disease characteristics were summarized using descriptive statistics. The proportion of patients (95% CI) in the ETN 50 mg and placebo groups who achieved each conventional clinical and NSAID-sparing endpoint at Week 8 was analyzed using logistic regression, with the corresponding baseline scores and treatment group included as covariates. For analyses of the NSAID-sparing endpoints,

when diary data were missing for a specific day, the missing data were counted as no intake. In addition, both a last observation carried forward method and a baseline observation carried forward approach (when no postbaseline diary data were available) were used. The estimated treatment difference (95% CI) was calculated as the difference between the proportion of patients treated with ETN who achieved the endpoint and the proportion of patients treated with placebo who achieved the endpoint.

To determine the capacity to discriminate between the treatment effects of ETN and placebo for each of the clinical and NSAID-sparing endpoints alone and in combination, OR (95% CI) were estimated from logistic regression models; the highest OR denoted the highest discriminant capacity in favor of ETN versus placebo.

RESULTS

Patients. Of 128 screened patients, 90 (ETN, $n = 42$; placebo, $n = 48$) were randomized into the 8-week, double-blind treatment period and included in the ITT population; 66 patients (ETN, $n = 33$; placebo, $n = 33$) completed the double-blind period. Patients in the ETN and placebo treatment groups had similar demographic and disease characteristics at baseline (Table 1). Of the 90 randomized patients, 51 (57%) had radiographic sacroiliitis and 45 (50%) had sacroiliac joint inflammation on magnetic resonance imaging.

Clinical and NSAID-sparing effects. At Week 8, statistically significant between-group differences, favoring ETN over placebo, were found in the proportions of patients achieving BASDAI50, BASDAI ≤ 3 , ASAS40, and ASDAS < 2.1 , but not in the proportions achieving ASAS20 or ASDAS < 1.3 (Figure 1A). Significantly more patients receiving ETN than patients receiving placebo achieved each of the NSAID-sparing endpoints (i.e., an ASAS-NSAID score of 0, ASAS-NSAID score < 10 , and a 50% reduction in ASAS-NSAID score). Statistically significant between-group differences were seen with 10 of 12 BASDAI combinations, 8 of 12 ASAS combinations, and 9 of 12 ASDAS combinations (Figure 1B–1D).

Discriminant capacity of clinical/NSAID-sparing outcome measures. The OR for the discriminant capacity of the clinical and NSAID-sparing outcome measures, alone and in combination, are shown in Figure 2. The majority of outcome measures (34 of 45) achieved statistical significance ($\alpha = 0.05$) in discriminating between the treatment effects of ETN and placebo. Observed treatment effects for clinical and NSAID-sparing measures individually and in combination ranged from an OR of 1.6 (95% CI 0.5, 5.4) for ASDAS < 1.3 alone to 5.8 (95% CI 1.2, 29.1) for BASDAI50 and NSAID score of 0. Combined outcome variables (i.e., clinical + NSAID-sparing) were found to be at least as discriminant as single (i.e., clinical) outcome variables; the majority of combined outcome variables using OR were more discriminant than single outcome measures.

DISCUSSION

In our posthoc analysis of the SPARSE study, we found that clinical and NSAID-sparing outcome measures, individually

Table 1. Baseline demographics and disease characteristics. Safety population. Values are mean (SD) unless otherwise specified.

Variables	ETN, 50 mg, n = 42	Placebo, n = 48
Patient and disease characteristics		
Age, yrs	38.8 (12.3)	38.9 (11.4)
Female, n (%)	18 (42.9)	16 (33.3)
BMI, kg/m ²	25.7 (4.8)	25.9 (4.9)
HLA-B27–positive, n (%)	28 (66.7)	31 (64.6)
Duration since diagnosis of axSpA, yrs	6.0 (9.0)	5.5 (7.4)
Positive pelvic radiograph*, n (%)	24 (57.1)	27 (56.3)
MRI sacroiliitis-positive**, n (%)	21 (50.0)	24 (50.0)
ASAS axSpA criteria, n (%)		
Clinical arm	7 (16.7)	8 (16.7)
Imaging arm	32 (76.2)	37 (77.1)
NSAID intake		
ASAS-NSAID score [†]	98.2 (39.0)	93.0 (23.4)
Disease activity		
BASDAI, 0–100	6.0 (1.6)	5.9 (1.5)
ASDAS	3.4 (0.9)	3.2 (0.8)
ASDAS disease state, n (%)		
Inactive disease	0	0
Moderate disease activity	5 (11.9)	3 (7.0)
High disease activity	19 (45.2)	23 (53.5)
Very high disease activity	18 (42.9)	17 (39.5)
CRP level, mg/dl	1.0 (1.3)	0.9 (1.4)
Abnormal CRP level, n (%)	21 (50.0)	15 [‡] (34.9)

* Grade ≥ 3 unilaterally or grade ≥ 2 bilaterally based on 1984 modified New York criteria for radiographic axSpA. ** According to local rheumatologist or radiologist. [†] Last observation carried forward method, with imputation, intent-to-treat population. [‡] Fifteen of 43 patients in placebo/ETN 50 mg group with CRP levels available at baseline. Abnormal CRP = $> 1.25 \times$ the upper limit of normal (4.9 mg/l). Inactive disease = ASDAS < 1.3 , moderate disease activity = $1.3 \leq$ ASDAS < 2.1 , high disease activity = $2.1 \leq$ ASDAS < 3.5 , and very high disease activity = ASDAS ≥ 3.5 . ETN: etanercept; BMI: body mass index; axSpA: axial spondyloarthritis; MRI: magnetic resonance imaging; ASAS: Assessment of SpondyloArthritis international Society; NSAID: nonsteroidal antiinflammatory drug; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASDAS: Ankylosing Spondylitis Disease Activity Score; CRP: C-reactive protein.

and in combination, were useful tools in assessing differences between the treatment effects of ETN and placebo in patients with axSpA. In the overall analysis, ASDAS < 2.1 combined with NSAID-sparing endpoints (i.e., ASDAS < 2.1 and/or 50% decrease in NSAID score, ASDAS < 2.1 and/or NSAID score of 0, and ASDAS < 2.1 or NSAID score < 10) showed the highest treatment discriminant capacities of the outcome measures as a group, whereas ASDAS < 1.3 , individually and in combination with the NSAID-sparing endpoints, showed the lowest discriminant capacities. The duration of the randomized clinical trial was limited to 8 weeks, which might have been too short for a sufficient number of patients to achieve remission. Consequently, it cannot be excluded that this remission outcome would perform better with trials of longer duration. The results presented here for the dichotomous ASDAS < 2.1 endpoint confirm findings from the primary publication of the SPARSE study, which demon-




Figure 1. Estimated proportions of patients achieving (A) individual clinical and NSAID-sparing outcome measures, (B) combined BASDAI and NSAID-sparing outcome measures, (C) combined ASAS and NSAID-sparing outcome measures, and (D) combined ASDAS and NSAID-sparing outcome measures by treatment group at Week 8. Based on logistic regression analyses with baseline and treatment group as covariates; clinical endpoints, LOCF; and ITT population. ASAS: Assessment of SpondyloArthritis international Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ETN: etanercept; ITT: intent-to-treat; LOCF: last observation carried forward; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drug; PBO: placebo.

strated that ASDAS treated as a continuous variable had greater discriminant capacity than BASDAI in detecting differences in treatment effect²⁶. Differences between the discriminant capacities of other clinical measure combina-

tions (i.e., ASAS and BASDAI measures) appeared to be relatively small (with the exception of BASDAI50 and an NSAID score of 0, which had the highest OR of all measures). Two NSAID intake measures (i.e., 50% reduction




Figure 1. Continued

in NSAID intake and NSAID score of 0) were at least as discriminant as the conventional outcome measures; these results are of importance because when initiating anti-TNF therapy, clinicians also aim to decrease or discontinue NSAID use, particularly in patients at high risk of gastrointestinal, renal, or cardiovascular disease.

Our observation that outcome measures in combination were generally more discriminant than individual measures is also a clinically relevant finding that should be considered in the design and conduct of future clinical trials as well as the analysis of data collected in longitudinal observational studies (e.g., cohorts and registries). To allow for a more




Figure 2. Discriminant capacity of (A) individual clinical and NSAID-sparing outcome measures, and (B) combined clinical and NSAID-sparing outcome measures in axSpA at Week 8. Based on logistic regression analyses with baseline scores and treatment group as covariates. For combined endpoints, baseline NSAID score was also in the model. Highest OR = highest discriminant capacity of treatment effects. LOCF method and ITT population. ASAS: Assessment of SpondyloArthritis international Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; axSpA: axial spondyloarthritis; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ITT: intent-to-treat; LOCF: last observation carried forward; NSAID: nonsteroidal antiinflammatory drug.

robust analysis of these data, we calculated OR; the lower limits of the 95% CI for the OR may be particularly relevant to researchers when calculating sample size of new clinical trials.

To our knowledge, this double-blind, placebo-controlled study (i.e., the SPARSE study) was the first to assess the NSAID-sparing effect of an anti-TNF agent using the ASAS-NSAID score²⁵. The primary findings of this study²⁶ support the NSAID-sparing effects and symptomatic benefits of such treatment. Estimated between-group differences in the proportions of patients achieving NSAID-sparing endpoints ranged from 23% (for ASAS-NSAID score < 10, $p = 0.022$) to 34% (for $\geq 50\%$ decrease in ASAS-NSAID score, $p = 0.003$) after 8 weeks of treatment. Significant differences between the treatment groups in the proportions of patients achieving clinical endpoints at 8 weeks ranged from 21% (for BASDAI50, $p = 0.034$) to 32% (for ASDAS < 2.1, $p = 0.006$) in favor of the biologic agent. Interestingly, the treatment effects observed using the conventional outcome measures (e.g., ASAS responder criteria) were of a similar magnitude in our study, in which NSAID intake was tapered, as in other clinical trials, in which NSAID intake was maintained at stable levels during the control period^{31,32}. Similar results have also been reported in clinical trials of other anti-TNF agents in radiographic and nonradiographic axSpA^{33,34,35,36}, although comparison of these trials is more challenging because of differences in patient selection, treatment duration, and statistical methods. The relative consistency of results across these trials suggests that changes in NSAID intake do not alter the discriminant capacity of the conventional outcome measures.

Important attributes of the SPARSE study include the prospective, randomized, double-blind, placebo-controlled design and use of many different disease assessment tools. Limitations include the 8-week duration of the study's double-blind, placebo-controlled period, the relatively small number of patients evaluated ($n = 90$), and the amount of data found to be missing in patients' paper diaries (summarized in the primary publication²⁶). Data collection through electronic patient diaries or physician interviews may be preferable options in future studies.

This study's findings, which may influence future clinical trial design, indicate that reduced NSAID intake during treatment in patients with axSpA does not preclude demonstration of clinically relevant treatment efficacy with an anti-TNF agent. Although not surprising to clinicians after 15 years of experience with anti-TNF therapy in axSpA, confirmation of their observations in a clinical study setting is nonetheless meaningful. In addition, they suggest that clinical and NSAID-sparing outcome measures, individually and in combination, may be valid means of discriminating treatment effects in axSpA. However, further research is needed to examine more closely the validity of these combinations of "clinical" and "therapeutic" outcome measures, to

determine their relevance in patients with radiographic and nonradiographic axSpA, to establish the ideal combination of clinical and NSAID-sparing outcomes with the greatest discriminant capacity, and to confirm that similar results are attainable with other treatments and over other treatment durations.

ACKNOWLEDGMENT

The authors thank all patients, investigators, and medical staff who participated in the study. SPARSE study investigators: C. Benhamou, F. Berenbaum, P. Bertin, A. Cantagrel, B. Combe, E. Dernis, P. Dieude, L. Euler-Ziegler, B. Fautrel, P. Hilliquin, S. Lassoued, L. Marguerie, C. Miceli, M. Nguyen, B. Pallot-Prades, G. Razjbaum, T. Schaevebeke, M. Soubrier, and O. Vittecoq. Editorial/medical writing support was provided by D. McGuire of Engage Scientific Solutions.

REFERENCES

1. Miceli-Richard C, Dougados M. NSAIDs in ankylosing spondylitis. *Clin Exp Rheumatol* 2002;20 Suppl 28:S65-6.
2. Dougados M, Béhier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. *Arthritis Rheum* 2001;44:180-5.
3. Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. *Rheumatology* 2010;49:536-41.
4. Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum* 2005;52:1756-65.
5. Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann Rheum Dis* 2012;71:1623-9.
6. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis* 2012;71:1616-22.
7. Straube S, Tramèr MR, Moore RA, Derry S, McQuay HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. *BMC Gastroenterol* 2009;9:41.
8. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAID-induced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. *Ann Rheum Dis* 2007;66:417-8.
9. Schneider V, Lévesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. *Am J Epidemiol* 2006;164:881-9.
10. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. *Ann Rheum Dis* 2007;66:1296-304.
11. Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. *Am J Cardiol* 2009;103:1227-37.
12. Leeb BF, Schweitzer H, Montag K, Smolen JS. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. *J Rheumatol* 2000;27:205-11.

13. Bertin P, Taieb C. NSAID-sparing effect of glucosamine hydrochloride in patients with knee osteoarthritis: an analysis of data from a French database. *Curr Med Res Opin* 2014;30:271-7.
14. Lagnaoui R, Baumevielle M, Bégau B, Pouyanne P, Maurice G, Depont F, et al. Less use of NSAIDs in long-term than in recent chondroitin sulphate users in osteoarthritis: a pharmacy-based observational study in France. *Thérapie* 2006;61:341-6.
15. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. *Arthritis Rheum* 2007;56:555-67.
16. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al; Systemic Vasculitis Study Group of the Italian Society for Rheumatology. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2004;141:493-500.
17. Seror R, Dougados M, Gossec L. Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. *Clin Exp Rheumatol* 2009;27:807-13.
18. Fernández-Nebro A, Irigoyen MV, Ureña I, Belmonte-López MA, Coret V, Jiménez-Núñez FG, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naïve rheumatoid arthritis. *J Rheumatol* 2007;34:2334-42.
19. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis* 2006;65:753-9.
20. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol* 2001;28:1238-44.
21. van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewé R, et al; Assessment of SpondyloArthritis international Society. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. *Ann Rheum Dis* 2011;70:905-8.
22. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology* 2011;50:124-31.
23. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. *Ann Rheum Dis* 2009;68:1136-45.
24. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. *Br Med J* 1986;293:911-4.
25. Dougados M, Simon P, Braun J, Burgos-Vargas R, Maksymowych WP, Sieper J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/ epidemiological studies in axial spondyloarthritis. *Ann Rheum Dis* 2011;70:249-51.
26. Dougados M, Wood E, Combe B, Schaeferbeke T, Miceli-Richard C, Berenbaum F, et al. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. *Arthritis Res Ther* 2014;16:481.
27. Song IH, Rudwaleit M, Listing J, Sieper J. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. *Ann Rheum Dis* 2009;68:1701-7.
28. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286-91.
29. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. *Ann Rheum Dis* 2004;63:1438-44.
30. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al; Assessment of SpondyloArthritis international Society (ASAS). ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:1811-8.
31. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. *Arthritis Rheum* 2011;63:1543-51.
32. Dougados M, van der Heijde D, Sieper J, Braun J, Maksymowych WP, Citera G, et al. Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol* 2014;66:2091-102.
33. Landewé R, Braun J, Deodhar A, Dougados M, Maksymowych WP, Mease PJ, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Ann Rheum Dis* 2014;73:39-47.
34. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). *Ann Rheum Dis* 2013;72:815-22.
35. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al; ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006;54:2136-46.
36. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al; French Ankylosing Spondylitis Influximab Network. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. *Arthritis Rheum* 2008;58:88-97.